Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women

Abstract

Cervical scrapes from 116 British women referred with cervical cancer were tested for the presence of high oncogenic risk human papillomavirus (HPV) genotypes (HPVhr). Ninety-four per cent of the scrapes had one or more of these virus types and 66% were HPV16-positive. HPV18 was more frequent in adenocarcinoma. No evidence was found for an increased cancer risk associated with the HPV16 E6 350G variant. The HLA DRB1* and DQB1* alleles in these women and in 155 women with normal cytology and negative for HPVhrDNA were compared. DQB1*0301 alone (2P = 0.02) and in combination with DRB1*0401 (2P = 0.02) was found to be associated with cervical cancer. This was more marked in cancers positive for HPV types other than HPV16. In contrast, DRB1*1501 alone and in combination with DQB1*0602 was not significantly elevated in cancers overall, but did show some excess in HPV16-positive cancers (2P = 0.05), associated with HPV16-positive cervical cancers. Taking all cancers together, a marginally significant protective effect was found for DQB1*0501 (2P = 0.03) but no protective effect could be seen for DRB1*1301. © 2000 Cancer Research Campaign

Two Listeria monocytogenes Vaccine Vectors That Express Different Molecular Forms of Human Papilloma Virus-16 (HPV-16) E7 Induce Qualitatively Different T Cell Immunity That Correlates with Their Ability to Induce Regression of Established Tumors Immortalized by HPV-16

“…Expression of the viral proteins E6 and E7 by a subset of HPV can immortalize infected cells and then may later ensure progression to malignant disease (1,2). HPV strain 16 is associated with Ͼ50% of cervical cancer cases (3)(4)(5). E6 and E7 are expressed constitutively in HPV-16-induced cervical cancer (6) and are thus commonly investigated targets for cancer immunotherapy.…”

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions

“…With modern tests, over 95% of all cancers are HPV positive (Bosch et al, 1995;Walboomers et al, 1999;Cuzick et al, 2000) and 75-95% of high-grade CIN lesions are associated with a positive HPV test on exfoliated cells (de Roda Husman et al, 1995;Herrington et al, 1995;Burger et al, 1996;Clavel et al, 1999;Cuzick et al, 1999). These and other comparative studies have shown that HPV testing has a greater sensitivity for CIN II/III than cytology.…”

“…The epidemiological data supporting this assertion include reports that HPV DNA can be recovered from over 95% of all cervical tumours (Bosch et al, 1995;Walboomers et al, 1999;Cuzick et al, 2000), and that women infected with oncogenic HPV types have relative risks of 40-180 for the development of high-grade cervical disease (IARC, 1995;Olsen et al, 1995). Additionally, molecular studies have identified mechanisms by which high-risk HPV types contribute to carcinogenesis.…”

The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions

“…The amplicon was purified by electrophoresis on a low melting point agarose gel, followed by solubilisation of the agarose with agarase (AgarAce, Promega) and genotyping by direct sequencing (Cuzick et al, 2000) with a Cy5-labelled sequencing primer.…”